Table 1 Trial characteristics
From: The fading of reported effectiveness. A meta-analysis of randomised controlled trials
| Â | Pravastatin (n = 64) | Atorvastatin (n = 35) | ||||||
|---|---|---|---|---|---|---|---|---|
|  | Mean | ± SD | Min. | Max. | Mean | ± SD | Min. | Max. |
Year of publication | 1995.28 | ± 3.46 | 1990 | 2001 | 1999.40 | ± 1.82 | 1996 | 2001 |
Reported effect size* | -29.50 | ± 4.16 | -19.0 | -39.0 | -36.07 | ± 3.70 | -28.4 | -44.2 |
Baseline†| 205.62 | ± 47.78 | 134.4 | 344.0 | 198.05 | ± 35.05 | 143.0 | 340.3 |
Study size‡ | 595.77 | ± 1511.59 | 10 | 9014 | 328.71 | ± 686.64 | 22 | 3916 |
Treatment group§ | EG: 56 (87%); CG: 8 (13%) | EG: 31 (89%); CG: 4 (11%) | ||||||
| Â | Timolol (n = 75) | Latanoprost (n = 32) | ||||||
|  | Mean | ± SD | Min. | Max. | Mean | ± SD | Min. | Max. |
Year of publication | 1992.68 | ± 6.99 | 1978 | 2001 | 1999.06 | ± 2.00 | 1995 | 2001 |
Reported effect size | -6.55 | ± 1.56 | -3.65 | -11.3 | -6.83 | ± 1.53 | -3.5 | -9.8 |
Baseline | 25.94 | ± 2.49 | 20.8 | 38.7 | 24.07 | ± 2.13 | 19.3 | 28.2 |
Study size | 197.96 | ± 249.59 | 12 | 1198 | 152.81 | ± 195.57 | 20 | 829 |
Treatment group | EG: 12 (16%); CG: 63 (84%) | EG: 29 (91%); CG: 3 (9%) | ||||||